HTG, Inc. is a Tucson, Arizona-based provider of molecular technology solutions led by CEO TJ Johnson. Its core product is the qNPA™ molecular technology platform and a multi-plex gene expression testing platform for miRNA and mRNA measurement, translational medicine and diagnostic applications. The qNPA platform is in use at major academic and cancer research centers as well as by big pharma. The company closed the first tranche of a $15.7M Series D financing to support its growth. HTG intends to use the funding to drive adoption of its testing platform for validation and clinical applications across different therapeutic areas and to expand into new high-growth molecular diagnostic opportunities. The company also plans to hire additional personnel in 2011, including sales and marketing, operations and development scientists with diagnostics experience.

Total raised

$16M

Funding rounds

1

Latest round

Series D

Latest activity

Feb 2011